Late evolution of dilated coronary lesions  by Desmet, Walter et al.
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624FO-6 Emergent Angioplaaty for Acute Myocardial Infarction 
at a Community Hospital Without On-Site Cardiac 
Surgery 
Mandeeo Sinoh, Kirk N. Garratt, Ryan J. Lennon, Michael A. Kjelsberg, Bernard J. 
Gersh, Peter B. Berger, Fards K. Timimi, Robert J. Houlihan, Kevin T. Cragun, 
Christopher H. Crocker, David R. Holmes, Jr., Henry H. "ling, Mayo Clinic, Rochester, 
Minnesota. 
Background: Percutaneous coronary intervention (PCI) for acute myocardial infarction 
(AMI) at hospitals without on-site cardiac surgery (CABG) remains controversial. We 
studied the safety and efficacy of PCI perfoi'med for AMI at Immanuel St. Joseph's Hospi- 
tal (IS,J), with no on-site CABG, with our affiliate, St. Mary's Hospital (SMH}, the nearest 
center (85 miles away) with on-site CABG. 
Method and Results: ISJ and SMH are linked by a T3 telemedicine line to enable on line 
consultation with cardiology and surgical staff at SMH. We compared the results of emer- 
gent PCI for AMI (defined as ST-segment elevation/new LBBB, or non-ST -segment ele- 
vation MI with ongoing chest pain) from 3/00 to 8/01 at ISJ (n=94) with matched controls 
at SMH. Multiple logistic regression analysis developed a propensity score based on clin- 
ical and angiographic variables. The two groups were balanced for age, ST-segment ele- 
vation, anterior infamt, gender, prior revaeculadzation, congestive heart failure, 
hypertension, smoking status, and renal or peripheral vascular disease. The in-hospital 
outcomes were similar in the two groups (see Table). No patient required urgent CABG 
due to procedural related complication. 
Conclusion: Our initial experience of emergent PCI for AMI utilizing telemedicine at a 
community hospital without on-site CABG is favorable, and the results are comparable to 
those at a tertiary facility with on-site CABG. These data support the new ACC/AHA 
Guidelines for PCI for AMI at a center without on-site CABG. 
ABSTRACTS - ACCIS2002 (Angiography & Interventional Cardiology) JACC March 6, 2002 
Variable ISJ Hospital Saint Mary's Hospital P-Value 
N=g4 (%) N=94(%) 
Age, yr 63.1+12.3 62.9+11.8 0.91 
Male 72(77) 67(71 ) 0.41 
ST-elevation MI 67(71 ) 67(71 ) 1.0 
Anterior M I 18(19) 18(19) 1.0 
Procedural success 88(94) 90(96) 0.52 
In-hospital death 3(3) 2(2) 0.65 
CABG<24 hours 0(0) 0(0) 
In-hospital death, QMI, CABG 4(4) 3(3) 0.70 
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1125-3 Late Evolution of Dilated Coronary Lesions 
Walter Desmet, Joseph Dens, Jan Piessens, UZ Gasthuisberg, Leuven, Belgium. 
Background: Smaller studies have suggested late regression of the dilated site after 
coronary angioplasty. The aim of this study was to evaluate with quantitative coronary 
angiography (QCA) the natural history of changes that occur in the dilated segment 
between 6 months and 3 years follow-up after angioplasty. 
Methods: We studied a subpopulation of the NICOLE (Nlsoldipine for COronary artery 
disease in LEuven)-study, in which patients underwent a control angiography 6 months 
and 36 months after coronary angioplasty. Of 826 patients who underwent successful 
angioplasty of one or more lesions, a total of 359 had a first control angiography after 
187±11 days (6M) and a second follow-up angiography after 1050~149 days (36M) with- 
out intervening revascularization of any target vessel. The 435 dilated lesions in these 
patients were subdivided in 4 categories depending on their degree of stenosis (%DS) at 
the time of the first control angiogram. 
Results: 
Subgroup Number of %DS %DS Change p-value 
%DS 6 M lesions at 5 M at 36 M 36M-6 M Change 
<25 69 19.0 _+ 5.6 32.0 + 12.9 13.1 + 13.8 < 0.0001 
25-60 290 38.0 + 6.5 38.8 + 10.2 0.8 + 10.5 0.2 
51-75 71 58.4±6.8 47.6±14.5 -10.9+14.9 <0.0001 
>75 5 82.2±6.6 54.0_+8.0 -28.2+7.1 0.0009 
Mean + SD are given 
Conclusion: Dilated coronary lesions with > 50 %DS 6 months after coronary angio- 
plasty show significant regression over the ensuing 2.5 years, while lesions of intermedi- 
ate severit~ (25-50 %DS) remain stable and minimal lesions still progress. 
These findings may aid in clinical decision making. 
1125-4 Prevention of Clinical Events and Restenosis After 
Percutaneous Tranalumlnal Coronary Angloplasty With 
Trapldil: Results of the STARC II Study 
Aleardo Maresta, Marco Balducelli, Spencer B. King Ill, Roberto Latini, Tiziano Moccetti, 
Alessandro Monici-Preti. Elisabetta Varani, Aldo P. Maggioni, for the STARC II 
Investigators, Ospedale S. Maria delle Croci, Ravenna, Italy, Istituto Mario Negri, Milano, 
Italy. 
Background. Still 30-40% of pts have a significant degree of restenosis after PTCA even in 
the stent era. Trapidil (T), a drug with antiplatelet and antiproliferative activity (platelet- 
derived growth factor antagonism) was shown to prevent post-PTCA restenosis in humans. 
STARC I study, showed a significant reduction in restenosis (24.2% T vs 39.7% ASA). 
Methods. To confirm these data, STARC II tdal tested a 6-month administration of T in 933 
pts undergoing elective PTCA (200 mg tld vs placebo (P) on top of ASA), on the 1-year 
combined end-point of death, reinfarction and need for repeat revasculadzatlon. The study 
was randomized, multicenter, double-blind. A subgroup of 305 pts was also randomized to 
repeat coronary angiography (CA) at 6 months with central reading. 
Results. Baseline clinical and angiographic characteristics were similar in the two study 
groups. Stent was implantated in 57% of the pts. Pdmary end-point occurred in 18.0% of P 
and in 20.4% of T groups(p--0.37). When recurrence or worsening of angina was added as 
further clinical end-point, this summed up to 23.0% in P vs 27.7% in T group (p=0.12). 
Treatment had to be discontinued for untowards effects in 5.0% and 9.6% of pts, respec- 
tively in P and T groups (p=0.O2). The angiographic substudy showed a slightly better final 
minimal uminal diameter (MLD) for T treated pts (1.7¢0.64 mm vs 1.59±0.67 mm) and less 
MLD late loss (0.48 vs 0.65 mm). This was parficulady evident in patients treated with bal- 
loon alone (0.21 vs 0.48 mm). Binary restenosis rate (final stenosis 2 50%) was 31.7% in 
stented pts in T vs 21.7% in P group (p--0.29) while was 15.6% in the balloon alone pts in T 
and 35.3% in P group (p=0.068). 
Conclusion. T seems not to influence clinical outcome of pts treated with elective balloon 
PTCA with/without stenting. Angiographic data suggest a possible favorable effect on rest- 
enosis only in pts treated with balloon PTCA alone. 
1125-5 Safety Profile of Glycoprotein lib/Ilia Inhibitors in 
Octogenerians 
H. Mehrdad Sadeohi, Kishore J. Harjai, Harish R. Chandra. Robert D. Safian, William W. 
O'Neill, Cindy L. Gnnes, William Beaumont Hospital, Royal Oak, Michigan. 
Background: Patients > 80 years-old constitute a growing population with CAD who have 
higher complication rates during percutaneous interventions (PCI). While glyooprotein 
lib/Ilia receptor inhibitors (GPI) are increasingly utilized to reduce the incidence of 
isshemic complications after PCI, there is limited data regarding the use of GPf in this 
group, especially with respect to the risk of intrecranial hemorrhage. We looked at the 
safety profile of GPI in a cohort of octo-& nanogenerians undergoing PCI. Methods: All 
consecutive pts 2 80 years-old undergoing PCI with or without a GPI at William Beau- 
mont Hospital dudng the period of January 1998 and June 2001 were evaluated for clini- 
cal outcomes and bleeding complications. Results: 1392 consecutive pts _> 80 years-old 
underwent PCI with a GPI (n=459) and without a GPI (n=933). Patients treated with a 
GP I  were more likely to be male (57% vs 48%) but less likely to have peripheral vascular 
disease (19% vs 25%). However, there were no baseline differences between the 2 
groups with respect to age (83), hypertension (71% vs 75%), diabetes (26% vs 27%), 
stroke, ulcer disease, hematocdt, or creatinine. Bleeding & transfusion rates are shown 
in the table below. Conclusions: Even though patients _> 80 years-old treated with Glyco- 
protein lib/Ilia receptor inhibitors have more minor bleeding, there is no increased risk of 
major bleeding requiring transfusions or intrecranial hemorrhage. GPI appear to be safe 
in octo-& nanogenerians undergoing PCI. 
RESULTS 
GPI n=459 NO GPI n=933 p value 
Hematoma 18% 13% 0.02 
GI/GU bleeds 10% 2.5% 0.004 
CNS bleeds 0% 0% NS 
Transfusion 10% 9% NS 
Transfused Unit per Bleed 2,3 2.2 NS 
Hospitalization length (days) 4.6+-4.6 4.5+-6.4 NS 
Death 3% 2.8% NS 
1125-6 Morta l i ty  Af ter  Percutaneous Coronary Intervention in 
Cardiogenic Shock: A Predictive Model Based on 1,869 
Consecutive Patients in the ACC-NCDR Registry 
Lloyd W. Klein. Ronald Krone, Peter Block, Ralph G. Brindle, Richard E. Shaw, Charles 
McKay, Kathleen Hewitt. William S. Weintraub, for the ACC-NCDR Registry, Rush- 
Presbyterian-St. Luke's Medical Center, Chicago, Illinois, 
Background: Although percutaneous coronary intervention (PCI) in the setting of cardio- 
genie shock (CSHOCK) has high in-hospital mortality, the identity and relative impor- 
tance of variables predictive of in-hospital death remain controversial. 
Methods: Accordingly, we queded the 100,000-plus patient ACC-NCDR registry col- 
lected in 1998-2000 and evaluated the procedures in 1,859 consecutive patients under- 
going PCI for CSHOCK. 
Results: The mean age was 66±13 years with males predominating (62%). 81% under- 
went PCI for urgent/emergent indication and 54% had ongoing rest angina. The mean 
LVEF in 1,149 patients with concurrent LV grams was 39±17%. PCI was performed on C- 
type lesions in 40% and B 2 lesions in 37%. Stents were placed in 71%, PCI at multiple 
